Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057159539> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2057159539 endingPage "A230" @default.
- W2057159539 startingPage "A230" @default.
- W2057159539 abstract "To determine the utilization and predictors of Cyclophosphamide-Methotrexate-Fluorouracil (CMF) chemotherapy in women with early stage breast cancer. A longitudinal study was conducted including patients 66 years and above, diagnosed with stage I-III breast cancer using SEER cancer registry data linked with Medicare claims. Patients were divided into two groups as those receiving CMF chemotherapy and those receiving other chemotherapy. A patient was considered as receiving CMF chemotherapy if she started chemotherapy within six months and had a claim of Cyclophosphamide, Methotrexate and 5-Fluorouracil within one year of diagnosis. Multiple logistic regression was conducted to assess the predictors of CMF chemotherapy use. A total of 11,322 women received chemotherapy within the first six months and 24.4% of these (n = 2758) received CMF chemotherapy. A patient had 2.3 times greater odds of receiving CMF chemotherapy with each year increase in age. Patients who received a lymph node dissection had 1.4 times greater odds of receiving CMF chemotherapy than patients who did not receive it. Patients with stage II tumor had 1.5 times greater odds of receiving CMF chemotherapy than stage I patients. CMF use decreased by 23% with estrogen receptor positivity and 18% when radiation was administered to the patient. Patients with Charlson's comorbidity index ≥ 1 were 16% more likely to receive CMF chemotherapy than patients who had a Charlson's comorbidity score of 0. CMF use decreased overall with time. This study found that age, comorbidity index, estrogen receptor status, radiation and lymph node dissection were significant predictors of CMF chemotherapy. The use of CMF chemotherapy increased with age, comorbidity index and lymph node dissection and decreased with estrogen receptor positivity and irradiation. The declining time trend in the use of CMF chemotherapy probably indicates the increased use of newer chemotherapy regimens like the Anthracycline and Taxane based regimens." @default.
- W2057159539 created "2016-06-24" @default.
- W2057159539 creator A5010932016 @default.
- W2057159539 creator A5031411629 @default.
- W2057159539 creator A5044760063 @default.
- W2057159539 creator A5088875299 @default.
- W2057159539 date "2012-06-01" @default.
- W2057159539 modified "2023-10-16" @default.
- W2057159539 title "PCN125 Predictors of Methotrexate Containing Chemotherapy in Women Diagnosed With Early Stage Breast Cancer" @default.
- W2057159539 doi "https://doi.org/10.1016/j.jval.2012.03.1242" @default.
- W2057159539 hasPublicationYear "2012" @default.
- W2057159539 type Work @default.
- W2057159539 sameAs 2057159539 @default.
- W2057159539 citedByCount "0" @default.
- W2057159539 crossrefType "journal-article" @default.
- W2057159539 hasAuthorship W2057159539A5010932016 @default.
- W2057159539 hasAuthorship W2057159539A5031411629 @default.
- W2057159539 hasAuthorship W2057159539A5044760063 @default.
- W2057159539 hasAuthorship W2057159539A5088875299 @default.
- W2057159539 hasBestOaLocation W20571595391 @default.
- W2057159539 hasConcept C121608353 @default.
- W2057159539 hasConcept C126322002 @default.
- W2057159539 hasConcept C141071460 @default.
- W2057159539 hasConcept C143998085 @default.
- W2057159539 hasConcept C146357865 @default.
- W2057159539 hasConcept C151730666 @default.
- W2057159539 hasConcept C2776694085 @default.
- W2057159539 hasConcept C2776755627 @default.
- W2057159539 hasConcept C2779159551 @default.
- W2057159539 hasConcept C2781059491 @default.
- W2057159539 hasConcept C530470458 @default.
- W2057159539 hasConcept C71924100 @default.
- W2057159539 hasConcept C86803240 @default.
- W2057159539 hasConceptScore W2057159539C121608353 @default.
- W2057159539 hasConceptScore W2057159539C126322002 @default.
- W2057159539 hasConceptScore W2057159539C141071460 @default.
- W2057159539 hasConceptScore W2057159539C143998085 @default.
- W2057159539 hasConceptScore W2057159539C146357865 @default.
- W2057159539 hasConceptScore W2057159539C151730666 @default.
- W2057159539 hasConceptScore W2057159539C2776694085 @default.
- W2057159539 hasConceptScore W2057159539C2776755627 @default.
- W2057159539 hasConceptScore W2057159539C2779159551 @default.
- W2057159539 hasConceptScore W2057159539C2781059491 @default.
- W2057159539 hasConceptScore W2057159539C530470458 @default.
- W2057159539 hasConceptScore W2057159539C71924100 @default.
- W2057159539 hasConceptScore W2057159539C86803240 @default.
- W2057159539 hasIssue "4" @default.
- W2057159539 hasLocation W20571595391 @default.
- W2057159539 hasOpenAccess W2057159539 @default.
- W2057159539 hasPrimaryLocation W20571595391 @default.
- W2057159539 hasRelatedWork W153159590 @default.
- W2057159539 hasRelatedWork W1966841381 @default.
- W2057159539 hasRelatedWork W1989798994 @default.
- W2057159539 hasRelatedWork W2045344299 @default.
- W2057159539 hasRelatedWork W2147292731 @default.
- W2057159539 hasRelatedWork W2286908130 @default.
- W2057159539 hasRelatedWork W2380201224 @default.
- W2057159539 hasRelatedWork W2405246611 @default.
- W2057159539 hasRelatedWork W4214554217 @default.
- W2057159539 hasRelatedWork W4290321499 @default.
- W2057159539 hasVolume "15" @default.
- W2057159539 isParatext "false" @default.
- W2057159539 isRetracted "false" @default.
- W2057159539 magId "2057159539" @default.
- W2057159539 workType "article" @default.